Company news

Gyre Therapeutics, Inc. news in 2026

Gyre Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

November 5, 2026

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

August 7, 2026

Gyre Therapeutics Appoints Three New Members to its Board of Directors

July 16, 2026

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

May 12, 2026

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

May 7, 2026

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S. and China-based Fully Integrated Biopharmaceutical Company

May 5, 2026

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

May 4, 2026

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

March 16, 2026

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 11, 2026

Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline

March 1, 2026

Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

January 4, 2026

Decks in 2026